FDA sounds the alarm on Pfiz­er’s block­buster Xel­janz af­ter a high dose was linked to a high­er death rate, blood clots

The FDA is sound­ing a for­mal warn­ing about the po­ten­tial safe­ty haz­ard posed by a high dose of Pfiz­er’s block­buster Xel­janz, tak­ing a move that could put a se­ri­ous crimp in its block­buster sales rev­enue.

Their state­ment to­day in­cludes:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER